Saturday, 3 October 2026European Markets

MONTEA And 1 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Loading stream...

(VIANEWS) - MONTEA (MONT.BR), MELEXIS (MELE.BR), () are the highest sales growth and return on equity stocks on this list.

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. MONTEA (MONT.BR)

25.8% sales growth and 10.57% return on equity

Montea NV is a public regulated real estate company under Belgian law (GVV/SIR) that specialises in logistical property in Belgium, the Netherlands, France, and Germany. The company is a benchmark player in this market. Montea literally offers its customers the space they need to grow through versatile and innovative property solutions. In this way, Montea creates value for its shareholders. As of 31/03/2023 the property portfolio represented a total space of 1,889,054 m² spread across 92 locations. Montea NV has been listed on Euronext Brussels (MONT) and Euronext Paris (MONTP) since the end of 2006.

Earnings Per Share

As for profitability, MONTEA has a trailing twelve months EPS of €7.52.

PE Ratio

MONTEA has a trailing twelve months price to earnings ratio of 9.57. Meaning, the purchaser of the share is investing €9.57 for every euro of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.57%.

Yearly Top and Bottom Value

MONTEA's stock is valued at €72.00 at 02:20 EST, way under its 52-week high of €101.80 and way above its 52-week low of €62.20.

Dividend Yield

As claimed by Morningstar, Inc., the next dividend payment is on May 19, 2023, the estimated forward annual dividend rate is 3.3 and the estimated forward annual dividend yield is 4.55%.

Volume

Today's last reported volume for MONTEA is 8759 which is 37.71% below its average volume of 14062.

More news about MONTEA.

2. MELEXIS (MELE.BR)

9.6% sales growth and 41.13% return on equity

Melexis NV designs, develops, tests, and markets advanced integrated semiconductor devices primarily for the automotive industry in Europe, the Middle-East, Africa, the Asia Pacific, and North and Latin America. The company provides magnetic position, latch and switch, current, inductive position, tire monitoring, temperature, optical, pressure, and speed sensor ICs. It also offers embedded motor driver, fan and pump, LED, and pre driver ICs; and LIN transceiver, CAN transceiver, RFID Transceiver NFC Sensor tag ICs. The company was founded in 1988 and is headquartered in Ieper, Belgium. Melexis NV is a subsidiary of Xtrion N.V.

Earnings Per Share

As for profitability, MELEXIS has a trailing twelve months EPS of €4.87.

PE Ratio

MELEXIS has a trailing twelve months price to earnings ratio of 19.58. Meaning, the purchaser of the share is investing €19.58 for every euro of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 41.13%.

More news about MELEXIS.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com